文摘
Familial hypercholesterolemia (HeFH) is associated with high risk of coronary heart disease, stroke, peripheral vascular disease. Achieving target LDL-C levels in individuals with HeFH remains a challenge. Recently, monoclonal antibodies against PCSK9, alirocumab and evolocumab, have been developed. These antibodies administered in HeFH further reduce LDL-C.